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ocrit (53 v 41), magnesium (2.1 v 2.0), platelet count (209,000 v 209,000), potassium (4.4
v 4.7), calcium (9.4 v 9.4), SBP during infusion (118 v 128). Change in FMD from base-
line to 15th infusion was not significantly different between groups (∆ FMD % chelation:
mean = 2.39; ∆ FMD % placebo: mean = -.53, p=.453).
Conclusions: PACT provides reassuring randomized data concerning a large number of
safety parameters monitored over a 15-week course of chelation therapy with EDTA. The
most reliable data concerning the safety and efficacy of chelation therapy for patients
with CHD will emerge from the NIH-funded Trial to Assess Chelation Therapy (TACT),
which will randomize 2,372 patients in a 2x2 factorial trial of EDTA and/or high-dose vita-
mins.
1023-90 Effects of Nitroglycerin on Erythrocyte Rheology and 
Oxygen Unloading: Microvascular Mechanisms in 
Relieving Myocardial Ischemia
Jian-Ping Bin, Howard Leong-Poi, Nicholas G. Fisher, D. Elizabeth Le, Jonathan 
Christiansen, Sanjiv Kaul, University of Virginia, Charlottesville, VA
Purpose: We hypothesized that myocardial blood flow (MBF) is enhanced to ischemic
tissue by the direct effect of nitroglycerin (NTG) on erythrocyte rheology and that anti-
ischemic effects of NTG are also afforded by its direct effects on O2 unloading .
Background: Investigations of the anti-ischemic properties of NTG, have been generally
focused on its systemic and coronary hemodynamic effects. At the microcirculatory level,
however, erythrocyte rheology and O2 unloading play an important role in determining
MBF and O2 delivery, respectively.
Methods and Results: Twelve dogs were studied at rest and during direct intracoronary
infusion of NTG (0.3-0.6µg·kg-1·min-1). All dogs had a resting flow-reducing single-vessel
stenosis. Half the dogs also had total occlusion of the remote coronary artery to remove
any collateral effects. Hemodynamics, MBF, WBη, erythrocyte charge (EC) and electroki-
netic mobility (EM), regional myocardial O2 delivery and consumption as well as tissue
O2 pressure (PO2) were determined. As compared to baseline, no changes in hemody-
namics were seen during intracoronary NTG. MBF increased significantly in the central
25% of the myocardium supplied by stenosis, which was associated with an approxi-
mately 19% decrease in WBη. There was a good correlation (r=0.87) between the two.
The decrease in WBη was caused by a decrease in EC and an increase in EM (r=0.83).
As compared to baseline, the % increase in tissue PO2 was significantly greater during
NTG than the % increase in MBF, indicating enhanced O2 unloading.
Conclusions: NTG directly affects microcirculatory erythrocyte rheology that is associ-
ated with an increase in MBF in the center of the ischemic bed. It also directly enhances
O2 unloading to the ischemic myocardium. Thus, direct microvascular affects of NTG
also contribute to its anti- ischemic properties.
1023-91 Relationship Between β-Adrenergic System 
Polymorphisms and Coronary Peak Flow Velocity Ratio 
in Women: Analysis From the National Heart, Lung, and 
Blood Institute-Sponsored Women's Ischemia 
Syndrome Evaluation (WISE)
Issam Zineh, Susan P. McGorray, Lacy L. Jernigan, Dennis M. McNamara, Daniel F. 
Pauly, C. Noel Bairey Merz, Carl J. Pepine, Julie A. Johnson, University of Florida, 
Gainesville, FL
Background: Coronary microvascular dysfunction is frequent in women presenting with
ischemic symptoms, but the pathophysiological basis is unclear. Genetic polymorphisms
in the adrenergic system were evaluated to gain insight into possible pathophysiological
mechanisms.
Methods: We studied WISE participants who underwent coronary angiography for evalu-
ation of ischemic symptoms. Angiography with Doppler ultrasonography was used to
measure average peak velocity ratio (APV-R) response to adenosine (Ad), acetylcholine
(Ach), and nitroglycerin (NTG). Patients were genotyped for polymorphisms of the β1-
adrenergic receptor (AR) (codons 49 and 389), β2AR (codons 16 and 27), and Gsα
(codon 131) using single-primer extension or luciferase-based assays. ANOVA and t-
tests were performed to compare the reactivity parameters by genotype. Data are pre-
sented as means ± SD. Due to significant differences in variant alleles by race, p-values
were adjusted for genotype-by-race interaction.
Results: Polymorphisms in the β1AR, β2AR, and Gsα were associated with differences in
APV-R response to NTG. Ser49 homozygotes (n=69) had diminished response com-
pared with Gly49 carriers (n=34), with APV-R of 2.14 ± 0.58 and 2.47 ± 0.62, respectively
(p=0.039). APV-R at codon 16 for Arg16Arg (n=26), Arg16Gly (n=48), and Gly16Gly
(n=29) were 2.27 ± 0.58, 2.33 ± 0.65, and 2.11 ± 0.59 (p=0.029). APV-R at codon 27 for
Gln27Gln (n=45), Gln27Glu (n=50), and Glu27Glu (n=9) were 2.28 ± 0.63, 2.32 ± 0.61,
and 1.82 ± 0.36, respectively (p=0.039). Finally, at Gsα codon 131, APV-R for +/+ (n=23),
+/- (n=51), and -/- (n=29) were 2.52 ± 0.62, 2.19 ± 0.65, and 2.19 ± 0.53 (p=0.036). β1AR
codon 389 (Arg◊Gly) was not associated with APV-R response to NTG in this population
(p=0.18). There were no associations between any genotypes and reactivity response to
Ad or Ach.
Conclusion: Polymorphisms in βARs and their G protein are associated with differences
in APV-R response to NTG in women undergoing angiography for evaluation of ischemic
symptoms. These data indicate a potential role of the adrenergic system in microvascular
dysfunction.
1023-92 Potential Beneficial Effects of Transdermal Capsaicine 
Patches on the Ischemic Threshold in Patients With 
Stable Coronary Disease
Gabriele Fragasso, Altin Palloshi, Maria Luisa De Benedictis, PierMarco Piatti, Lucilla 
Monti, Emanuela Setola, Alberto Cappelletti, Alberto Margonato, Istituto Scientifico/
Universita' San Raffaele, Milano, Italy
Background. Capsaicin has been shown to exert direct vasodilating effects through
increased calcitonine gene-related peptide (CGRP) release. However no data exist on its
effect following systemic administration.
Methods. Twelve male patients with stable coronary disease were selected for study. All
patients had a persistently positive exercise test despite full antianginal therapy. Accord-
ing to a double blind, placebo-controlled study, patients were randomised to placebo or
3g oleic capsaicin-containing patches, in 2 different days and with a 2-day interval
between treatments. Patients performed treadmill exercise testing according to the Bruce
protocol. Heart rate, systolic/diastolic blood pressure and rate-pressure product were
measured at rest, at the appearance of 1mm ST segment depression and at peak exer-
cise. Time to 1mm ST segment depression and to peak exercise, maximal ST segment
depression, cumulative maximal ST segment depression and the number of ECG leads
showing diagnostic changes were also measured. Blood samples for nitric oxide (NO)
and CGRP were drawn at baseline, at peak exercise, 2, 6 and 24 hours after exercise.
Results. On placebo, all patients had a positive ECG during exercise test. Only one
patient experienced angina, in both treatments. With capsaicin, 1 patient had a negative
exercise, while the remaining 11 increased time to 1mm ST depression (from 372±170 to
424±182 sec, p<0.03) and time to peak exercise (from 489±189 to 508±202 sec, p=0.29)
and decreased the total number of involved ECG leads (from 3.75±1.76 to 3.25±2.00
leads, p=0.05). CGRP levels were not significantly different between placebo and capsa-
icin treatment. Conversely, when on capsaicin, NO significantly increased at 6 hours. No
significant side effects were recorded. Conclusions. Transdermal capsaicin may
improve ischemic threshold in patients with stable coronary disease, probably through
NO-mediated arteriolar vasodilation
1023-93 Anti-Inflammatory Effects of the V-Protectant AGI-1067 
in the Canadian Antioxidant Restenosis Trial (CART-1)
Jean-Claude Tardif, Philippe L. L'Allier, Leonard Schwartz, Lawrence Title, Louise 
Laramee, Francois Reeves, Joel Lavoie, Marie-Claude Guertin, Jean Gregoire, Montreal 
Heart Institute, Montreal, PQ, Canada
AGI-1067, the mono-succinic acid ester of probucol, is a lipophilic vascular protectant
that reduces the expression of VCAM-1 and MCP-1 and has strong antioxidant proper-
ties equipotent to probucol. We have shown in CART-1 that AGI-1067 has favorable
effects on restenosis and the atherosclerotic non-PCI (reference) segments (Circulation
2003;107:552-8). The objective of the present study was to determine the effects of AGI-
1067 on markers of inflammation. Prior to PCI, 305 pts were randomly assigned to 1 of 5
treatment groups: placebo (n=61); probucol 500 mg BID (n=60); AGI-1067 70 mg (n=59),
140 mg (n=64), or 280 mg (n=61) QD. Pts were treated for 2 wks prior to and for 4 wks
after PCI. Fibrinogen plasma levels and circulating white blood cell (WBC) counts were
measured at baseline and at the end of the 6-wk dosing period. Results: Plasma levels of
fibrinogen at baseline were 3.73+/-1.29 in the placebo group, 3.70+/-0.98 in the probucol
group, and 3.63+/-1.13, 3.78+/-0.81 and 3.70+/-0.83 gm/L in the AGI-1067 70, 140 and
280 mg groups respectively (p=NS). After 6 wks of treatment, fibrinogen levels were
3.56+/-0.76 in the placebo group, 3.63+/-1.05 in the probucol group, and 3.37+/-1.17,
3.17+/-0.65 and 3.21+/-1.01 gm/L in the AGI-1067 70, 140 and 280 mg groups respec-
tively (p=0.03 for AGI-1067 140 mg vs placebo; p=0.07 for AGI-1067 280 mg vs placebo;
p=0.005 for AGI-1067 140 mg vs probucol; p=0.017 for AGI-1067 280 mg vs probucol).
WBC counts decreased from baseline to end of treatment by 0.51+/-1.31 in the placebo
group, 0.79+/-1.48 in the probucol group, and 0.59+/-2.06, 0.88+/-1.40 and 1.09+/-1.26 in
the AGI-1067 70, 140 and 280 mg groups respectively (p=0.025 for AGI-1067 280 mg vs
placebo; p=NS for probucol vs placebo). Fibrinogen levels after 6 wks of treatment corre-
lated inversely (p=0.07) with the previously described favorable effect induced by AGI-
1067 in atherosclerotic reference segments as assessed by intravascular ultrasound.
Conclusion: The vascular protectant/antioxidant AGI-1067 has anti-inflammatory effects
in patients with atherosclerosis. The CART-2 and ARISE (Aggressive Reduction of
Inflammation Stops Events) trials are testing the anti-inflammatory hypothesis with AGI-
1067.
1023-94 Comparative Effect of Trimetazidine Plus Sildenafil 
Versus Nitrates in the Control of Myocardial Ischemia 
During Sexual Activity
Giuseppe M. Rosano, Roberto Patrizi, Giuseppe Marazzi, Elena Cerquetani, Massimo 
Fini, Giuseppe Mercuro, San Raffaele Roma, Roma, Italy, University of Cagliari, Cagliari, 
Italy
A large proportion of patients with erectile dysfunction (ED) have coronary artery disease
(CAD). In these patients nitrate therapy that is a contraindication to the use of Sildenafil.
In order to assess whether trimetazidine is effective in controlling episodes of myocardial
ischemia during sexual activity in patients with (CAD) receiving chronic nitrates we stud-
ied 38 male patients (57+6 years) with proven CAD. Patients underwent 24 hour ECG
monitoring (AEM) at baseline, after one week of oral nitrate therapy (20 mg tds) and after
one week of Trimetazidine (20 mg tds). Patients were asked to have at least one sexual
intercourse during each AEM. Patients were instructed to take Sildenafil (100 mg) one
hour before the sexual intercourse performed at baseline and during therapy with Tri-
metazidine and Sildenafil Placebo (in blind) during therapy with nitrates. An improvement
in total ischemic burden was observed with both nitrates and Trimetazidine compared to
baseline (-3+2 vs –5+3 episodes/24 hours, p=0.07; -6+5 vs –8+3 minutes/24 hours,
p=0.07). Trimetazidine plus Sildenafil were more effective in controlling episodes of myo-
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cardial ischemia during sexual activity than nitrates alone (-45+11% vs –18+7%, p<0.04).
In conclusion patients with cardiovascular disease receiving chronic nitrate therapy may
be safely switched to Trimetazidine in case of need of therapy for ED. The association
between Sildenafil and Trimetazidine is more effective than nitrate therapy in the control
of ischemic episodes during sexual activity.
1023-95 Excessive Bleeding With Aspirin, Clopidogrel, and 
Warfarin "Triple Therapy"
Adam B. Greenbaum, Ghadi G. Ghorayeb, Michael P. Hudson, Laila M. Poisson, W. 
Douglas Weaver, Henry Ford Heart and Vascular Institute, Detroit, MI
Background: Numerous medical conditions require patients to receive chronic anti-
thrombin therapy. Recent guidelines support longer and more aggressive antiplatelet
therapy after myocardial infarction (MI) and following drug-eluting stent implantation or
intravascular radiation. Currently, there is no safety data supporting or warning against
the use of "triple therapy" with aspirin, clopidogrel and warfarin and practice patterns
vary. Our aim was to estimate the risk and severity of bleeding complications in patients
receiving "triple therapy". Methods: Via electronic medical records search, 110 patients
either discharged on or receiving >2 consecutive days of "triple therapy" while hospital-
ized were identified and data collected regarding baseline demographics and laboratory
values, indication for therapy and bleeding complications. Comparisons were made
between those with and without bleeding and to historical controls. Results: The overall
population was representative of those requiring antiplatelet and/or antithrombin therapy;
mean age 68+12, 63% male; 47% prior MI; 19% prior stroke. Indication for warfarin: 35%
atrial fibrillation; 35% apical thrombus/low ejection fraction. Indication for antiplatelet ther-
apy: 70% PCI; 20% acute coronary syndrome. Bleeding occurred in 25 (23%) of patients;
14% TIMI major; 9% TIMI minor; 6% gastrointestinal; 1% intracranial; median time to
major bleeding: 7 (5, 18) days. Patients who bled were more likely to be female, non-
smokers, have renal insufficiency and a prior stroke. No differences were noted in indica-
tion for therapy, aspirin dose, baseline labs or peak INR between those with and without
bleeding (mean INR at time of bleed; 1.8+1.3). Conclusion: This is the first and only
known estimate of the clinical bleeding risk on "triple therapy" with aspirin, clopidogrel
and warfarin. There appears to be a significantly greater and excessive overall and TIMI
major bleeding risk compared to historical controls with mono- or dual therapy (23% vs 1-
10% and 14% vs 1-4%, respectively, p<0.0001). This was independent of aspirin dose
and INR level. Confirmation is warranted as the implications are vast.
1023-96 A Randomized Double-Blind Placebo-Controlled Phase 
2 Study on the Efficacy and Safety of Fasudil in Patients 
With Stable Angina
Ralph M. Vicari, Bernard Chaitman, Deborah Keefe, William B. Smith, Steven G. 
Chrysant, Melvin J. Tonkon, Neville Bittar, Robert J. Weiss, Udho Thadani, The Fasudil 
Study Group, St. Louis University School of Medicine, St. Louis, MO, University of 
Oklahoma, Oklahoma City, OK
Background: Fasudil, an orally available rho-kinase inhibitor, selectively inhibits coro-
nary arterial vasoconstriction without affecting systemic hemodynamics. Therapeutic
doses in patients with stable angina have not been previously determined.
Methods: In a phase II, multicenter, double-blind, placebo-controlled randomized trial,
we evaluated the effects of fasudil on total exercise duration and time to onset of myocar-
dial ischemia (> 1 mm ST-segment change) in patients with stable angina. Anti-anginal
medications were limited to nitroglycerin prn and monotherapy with either a beta- or cal-
cium-channel blocker. Cardiovascular medications including aspirin, statins, and ACE
inhibitors were allowed. Patients of either sex were required to have objective evidence of
myocardial ischemia, reproducible baseline exercise test times, and exercise-induced ST
segment depression > 1 mm. A total of 84 of the 206 patients screened met entry criteria
and were randomized 1:1 to placebo or fasudil for efficacy analysis. After a 3-week wash-
out period, fasudil or matching placebo were force-titrated from 20 mg tid to 80 mg tid
with 20 mg tid increments every 2 weeks. Efficacy was evaluated by symptom-limited
exercise testing after eight weeks of therapy.
Results: Exercise duration at 8 weeks was increased by 1.43 min (86.1 seconds) in the
placebo group, and by 1.97 min (118.4 seconds) in the fasudil group (both p<0.001 vs
baseline and p=ns to each group). Time to onset of myocardial ischemia was increased
by 2.83 min in the fasudil group compared to placebo at 8 weeks (p=0.012). Heart rate
and blood pressure were unchanged in both groups. A 10% discontinuation rate due to
adverse events was evenly divided between the two groups.
Conclusions: This dose-finding trial demonstrated that titrating fasudil to 80 mg tid
improves exercise time and time to exercise-induced myocardial ischemia in stable
angina patients, and is well tolerated.
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1041-89 Oxygen Free Radical Damage to Essential Components 
of the Oxidative Phosphorylation Pathway
Melanie Y. White, Stuart J. Cordwell, Hugh C.K. McCarron, Adrian S. Tchen, Brett D. 
Hambly, Richmond W. Jeremy, The University of Sydney, The University of Sydney, 
Australia, Australian Proteome Analysis Facility, Macquarie University, Australia
Background: Stunned myocardium is characterized by impaired contractile function, and
oxygen free radicals (OFR) are known to contribute to the pathogenesis. Oxidative phos-
phorylation is maintained in stunning, but abnormal phosphate / oxygen (P/O) ratios sug-
gest limited uncoupling of electron transport. Recent studies have shown mitochondria
are particularly sensitive to damage resulting from ischemia / reperfusion injury.
Methods: Left ventricular (LV) samples were taken from rabbit hearts after 75 min nor-
mal perfusion (control; n=6) or 15 min low flow (1 ml/min) ischemia followed by 60 min
reperfusion (stunned; n=6). A third group underwent 15I/60R with the hydroxyl radical
scavenger, N-(2-mercaptopropionyl) glycine (3 mM) added to the perfusate (15I/
60R+MPG; n=6). Isovolumic LV pressure was measured throughout. Whole cell protein
profiles were generated by two-dimensional gel electrophoresis and image analysis used
to identify differentially expressed proteins, with mass spectrometry to identify proteins
and define modifications.
Results: Rate pressure product at the end of the protocol was impaired in 15I/60R
(61+6% baseline) in comparison to control (90±6%, mean + SEM; p>1.5-fold difference
in visible abundance). 42 proteins were shown to be modified in 15I/60R samples, 15 of
which were functionally associated with redox metabolism, including 5 NADH ubiquinone
oxidoreductase subunits, cytochrome c reductase and oxidase and two ATP synthase
subunits. Treatment with MPG reversed the majority (n=13/15) of the observed modifica-
tions, but not that seen for NADH Uq 27kDa.
Discussion: Ischemia / reperfusion is associated with multiple alterations to mitochon-
drial electron transport system proteins and the ATP proton pump, which are prevented
by treatment with MPG. The change to NADH Uq 27kDa was not as pronounced follow-
ing the addition of MPG suggesting a two stage insult to this subunit occurring in both the
ischemic and reperfusion periods. These data demonstrate another mechanism by which
OFR contribute to dysfunction of reperfused myocardium.
1041-90 Opening of the Mitochondrial Potassium Adenosine 
Triphosphate Channel Improves Postanoxic Recovery 
of Conduction and Excitation-Contraction Coupling in 
the Developing Heart
Sarre Alexandre, Lange Norbert, Kucera Pavel, Eric Raddatz, Institute of Physiology, 
Lausanne, Switzerland
Background: Activation of the mitochondrial KATP (mitoKATP) channel is thought to pre-
condition the adult heart via ROS production. To what extent modulation of mitoKATP
channel alter oxidative stress and activity of the hypoxic-reoxygenated developing heart
is not known.
Methods: Spontaneously beating hearts were dissected from 4-day-old chick embryos,
mounted in vitro and submitted to 45 min normoxia (21% O2), 30 min anoxia (0% O2)
and 60 min reoxygenation (21% O2) at 37°C. The time-course of ROS production in the
ventricle was determined by measuring changes in fluorescence resulting from oxidation
of the intracellular probe DCFH (10 µM) and expressed as arbitrary units per second
(a.u./s). Involvement of the mitoKATP channel in oxidative stress was assessed by using
the opener diazoxide (DIAZO, 50µM) or the blocker 5-hydroxydecanoate (5-HD, 500 µM).
The nonselective KATP channel blocker Glibenclamide (Glib, 1µM) was also tested. Elec-
trocardiogram and atrial and ventricular contractions were continuously recorded during
experiments. Reoxygenation-induced chrono-, dromo- and inotropic disturbances,
arrhythmias and alterations of electromechanical delay (EMD) in atrium and ventricle
were systematically investigated.
Results: Under normoxia, heart rate (169 ± 24 bpm), PR interval (128 ± 20 ms), ventricu-
lar shortening velocity (1.9 ± 1.3 mm/s), atrial EMD (14 ± 3 ms) and ventricular EMD (9 ±
2 ms) (mean ± SD, n= 6) were similar in all groups. ROS production in control hearts was
0.18 ± 0.06 under normoxia and peaked at 1.02 ± 0.37 a.u./s (n= 6) after 10 min of reox-
ygenation. With respect to control, DIAZO, 5-HD, DIAZO+5-HD or Glib altered neither
ROS production nor functional parameters under steady normoxia. During reoxygen-
ation, 5-HD alone or Glib had no effect, while DIAZO doubled the burst of free radicals
and increased the rate of recovery of PR interval and ventricular EMD. This DIAZO-
induced protection was abolished by 5-HD.
Conclusion: In the developing heart, unlike in adult, it appears that pharmacological acti-
vation of the mitoKATP channel is prooxidant and improves atrio-ventricular conduction
and ventricular excitation-contraction coupling specially during reoxygenation.
